Literature DB >> 16380661

[The incidence rate of hepatitis B virus surface gene variants in Korean children with immunoprophylaxis failure of perinatal infection].

Jong-Hyun Kim1, Dae Kyun Koh, Jae Kyun Hur, Jin Han Kang, Omana V Nainan, Harold S Margolis.   

Abstract

BACKGROUND/AIMS: Perinatal infection with hepatitis B virus (HBV) may occur despite immunoprophylaxis. One of the important mechanisms for perinatal prophylaxis failure, might include HBV surface gene variants. Therefore, we screened Korean children, in whom perinatal prophylaxis failed, for HBV surface gene variants.
METHODS: Thirty-one children with perinatal HBV prophylaxis failure were selected. To amplify the major hydrophilic region of the HBV surface gene, nested PCR with primers targeted to nucleotides 237 to 706 was performed, and then sequencing was done.
RESULTS: All cases were shown to be PCR positive for HBV-DNA and genotype C. Nine out of 31 (29%) with perinatal prophylaxis failure had a nucleotide substitution at the major hydrophilic region of the gene; but only two cases (6.5%) had an amino acid substitution. One case was infected by wild type and variants of I126S, and the other by wild type and S114A+I126S, respectively.
CONCLUSIONS: In Korea, compared to the previous studies of other nations, gene surface variants such as G145R do not appear to play an important role in perinatal immunoprophylaxis failure.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16380661

Source DB:  PubMed          Journal:  Korean J Hepatol        ISSN: 1738-222X


  2 in total

1.  Clinical study on the relationship between hepatitis B virus infection and risk of breast cancer: a large sized case-control and single center study in southwest of China.

Authors:  Lin-Jie Lu; Vishnu Prasad Adhikari; Chun-Xia Zhao; He Wu; Wei Dai; Xin Li; Hong-Yuan Li; Guo-Sheng Ren; Kai-Nan Wu; Ling-Quan Kong
Journal:  Oncotarget       Date:  2017-07-10

2.  Lamivudine therapy for korean children with chronic hepatitis B.

Authors:  Hong Koh; Seoung Yon Baek; Ki Sup Chung
Journal:  Yonsei Med J       Date:  2007-12-31       Impact factor: 2.759

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.